VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Muhammad Ali’s daughter: “Dad, you are a pearl embedded in the oyster of life”
WPC highlights: May May Ali and Brian Grant at the opening ceremony
3 weeks ago
Plant-based compounds could treat chronic pain in Parkinson’s, study finds
A six-year study has found that chronic pain in people with Parkinson’s is linked to a gene involved with how the brain responds to cannabis compounds. The investigation examined why some people with the condition experience persistent pain – and the impact it has on their work, daily life and social relationships. Conducted by researchers at Manchester’s Salford Royal Foundation Trust, UK, and funded by Parkinson’s UK, it is the largest study to investigate chronic pain in people with Parkinson’s. Dr Monty Silverdale, consultant neurologist at Greater Manchester Centre, said: “This study is significant because it shows the important role of genetics in chronic pain in Parkinson’s. “Our findings suggest that cannabis-based compounds may be worth investigating as a treatment for pain in Parkinson’s.”
Could playing table tennis help reduce Parkinson’s symptoms?
Researchers at Fukuoka University, Japan, have found that playing table tennis may help alleviate motor symptoms in Parkinson’s. As part of the study, 12 people with Parkinson’s with an average age of 73 played a five-hour session of table tennis every week for a period of six months. The sessions were developed specifically for people with the condition by experienced table tennis players from the university’s department of sports science. The participants were evaluated after three months and at the end of the study. At both evaluations, participants had reduced symptoms – showing improvement in speech, handwriting, walking and hand tremors. Two participants reported side-effects of backache and falling. Study author Ken-ichi Inoue, MD, of Fukuoka University said: “While this study is small, the results are encouraging because they show ping pong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson’s disease. A much larger study is…
‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s
Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…